룩소리티닙
|
|
룩소리티닙 속성
- 녹는점
- 84-89°C
- 밀도
- 1.40
- 저장 조건
- -20°
- 용해도
- DMSO(최대 28mg/ml) 또는 에탄올(가온 시 최대 15mg/ml)에 용해됩니다.
- 물리적 상태
- 백색 분말.
- 산도 계수 (pKa)
- 11.63±0.50(Predicted)
- 색상
- 하얀색
- 안정성
- 제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°에서 최대 3개월 동안 보관할 수 있습니다.
- InChI
- InChI=1/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/s3
- InChIKey
- HFNKQEVNSGCOJV-UJHUVDBMNA-N
- SMILES
- [C@@H](C1CCCC1)(N1N=CC(C2N=CN=C3NC=CC=23)=C1)CC#N |&1:0,r|
- CAS 데이터베이스
- 941678-49-5
안전
- 위험 및 안전 성명
- 위험 및 사전주의 사항 (GHS)
HS 번호 | 29335990 | ||
---|---|---|---|
유해 물질 데이터 | 941678-49-5(Hazardous Substances Data) |
룩소리티닙 C화학적 특성, 용도, 생산
개요
In November 2011, the U.S. FDA approved ruxolitinib (INCB018424) for the treatment of patients with intermediate or high-risk myelofibrosis. Ruxolitinib is an ATP-competitive inhibitor of JAK1 and JAK2 (IC50's of 3.3±1.2 nM and 2.8±1.2 nM, respectively) and inhibition occurs regardless of the JAK2V617F mutational status. Ruxolitinib is a moderately potent inhibitor of the related JAK, TYK2 (IC50=19±3.2 nM) but is selective versus JAK3 (IC50=428±243 nM). It was also selective versus a panel of 26 other kinases at concentrations approximately 100-fold the IC50 of JAK1 and JAK2. Inhibition of JAK1 and JAK2 downregulates the JAK-signal transducer and activator of transcription (STAT) pathway, inhibiting myeloproliferation, inducing apoptosis, and reducing numerous cytokine plasma levels.Characteristics
Class: non-receptor tyrosine kinaseTreatment: MF, PV, cGVHD
Oral bioavailability >95%
Elimination half-life = 3 h
Protein binding = 97%
용도
Ruxolitinib is a selective Janus tyrosine kinase (JAK1 and JAK2) inhibitor used in the treatment of myeloproliferative neoplasms and psoriasis.Indications
The JAK family includes four isoforms, JAK1, JAK2, JAK3, and tyrosine kinase (TYK2). Ruxolitinib (Jakafi(R), Incyte Corp.) was the first approved JAK inhibitor, which inhibits both JAK1 and JAK2, used for the treatment of different types of myelofibrosis. Tofacitinib (Xeljanz(R), Pfizer) was approved by FDA as a JAK3-selective inhibitor for the treatment of rheumatoid arthritis and is one of the only two FDA-approved kinase inhibitors for non-oncological indications.정의
ChEBI: A pyrazole substituted at position 1 by a 2-cyano-1-cyclopentylethyl group and at position 3 by a pyrrolo[2,3-d]pyrimidin-4-yl group. Used as the phosphate salt for the treatment of patients with intermediate or high-risk myelofibrosis, includ ng primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.룩소리티닙 준비 용품 및 원자재
원자재
준비 용품
룩소리티닙 공급 업체
글로벌( 386)공급 업체
공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
---|---|---|---|---|---|
Zhengzhou Anhuida Chemical Co., Ltd | +8615903659408 |
admin@ahdchem.com | China | 294 | 58 |
TAIZHOU YUXIN BIOTECHNOLOGY CO,.LTD | +86-576-88902229;+86-0576-88902229 +8613968687450 |
yuxin@yuxchem.com | China | 158 | 58 |
Hebei Mojin Biotechnology Co., Ltd | +8613288715578 |
sales@hbmojin.com | China | 12450 | 58 |
Senova Technology Co. Ltd. | +86-0755-86703119 +8618503098836 |
info@senovatech.com | China | 351 | 58 |
shandong perfect biotechnology co.ltd | +86-53169958659; +8618596095638 |
sales@sdperfect.com | China | 294 | 58 |
Henan Bao Enluo International TradeCo.,LTD | +86-17331933971 +86-17331933971 |
deasea125996@gmail.com | China | 2503 | 58 |
Hangzhou ICH Biofarm Co., Ltd | +86-0571-28186870; +undefined8613073685410 |
sales@ichemie.com | China | 988 | 58 |
Guangzhou Tengyue Chemical Co., Ltd. | +86-86-18148706580 +8618826483838 |
evan@tyvovo.com | China | 153 | 58 |
Henan Fengda Chemical Co., Ltd | +86-371-86557731 +86-13613820652 |
info@fdachem.com | China | 20294 | 58 |
airuikechemical co., ltd. | +undefined86-15315557071 |
sales06@airuikechemical.com | China | 983 | 58 |
룩소리티닙 관련 검색:
DL-말산
Rucaparib
1-[[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol
Posaconazole
Calcium dobesilate
S-Ruxolitinib (INCB018424)
3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
Ruxolitinib phosphate
Ponatinib
Lenalidomide
Abiraterone
Gefitinib
Ibrutinib
Bortezomib
Y27632 (hydrochloride)
MK-2206 2HCl
Dasatinib
Trametinib